TNF inhibitors in the treatment of arthritis

Current Opinion in Investigational Drugs

Volumn 1, Issue 2, 2000, Pages 188-193

  Lorenz, H M ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; LENERCEPT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANKYLOSING SPONDYLITIS; BREAST CARCINOMA; CHRONIC DISEASE; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; GRANULOMATOSIS; HEART FAILURE; HUMAN; INFECTION COMPLICATION; INFLAMMATORY DISEASE; INJECTION SITE; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOMA; MUSCULOSKELETAL DISEASE; PAROTID GLAND CARCINOMA; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SQUAMOUS CELL CARCINOMA; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; XANTHOMA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033755173     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification)
2. Rheumatoid arthritis: Pathophysiology and implications for therapy
3. Taking mortality in rheumatoid arthritis seriously - Predictive markers, socioeconomic status and comorbidity
4. Long-term second-line treatment: A prospective drug survival study
5. Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium
6. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester
7. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells
8. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
9. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
10. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis
11. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to TNF-α
12. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid Arthritis
13. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects
14. Possible mechanism for the long-term efficacy of anti-TNF alpha antibody (cA2) therapy in RA
15. Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis
16. In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: Longterm effects after repeated infusion of chimeric monoclonal antibody cA2
17. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
18. Development of anti dsDNA antibodies in patients with rheumatoid arthritis treated with a chimeric monoclonal antibody to TNF alpha
19. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
20. 54-week clinical and radiographic results from the ATTRACT trial: A phase III study of infliximab (Remicade®) in patients with active RA despite methotrexate
21. The therapeutic effect of an engineered human antitumor-necrosis factor alpha antibody (CDP571) in rheumatoid arthritis
22. Serological effects of repeated doses of an engineered human anti-TNF-alpha antibody, CDP571, in patients with rheumatoid arthritis (RA)
23. Neutralization of TNF by lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis treated for three months: Results of a European phase II trial
24. Chronic TNF neutralization (up to 1 year) by lenercept (TNFR55-IgG1, Ro 45-2081) in patients with rheumatoid arthritis: Results of an open-label extension of a double-blind single dose phase I study
25. Neutralization of TNF by lenercept (TNFP55-iGg1, Ro 45-2081) in patients with rheumatoid arthritis treated for three months: Results of an US phase II trial
26. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor (p75)-Fc fusion protein
27. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
28. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid receiving methotrexate
29. Long-term safety and efficacy of combination therapy with methotrexate and etanercept
30. A phase III trial of etanercept vs. methotrexate (MTX) in early rheumatoid arthrtitis (Enbrel ERA trial)
31. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthrtitis - Resuts of a phase I study
32. A single dose placebo controlled phase I study of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis
33. Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis
34. Long-term treatment with the fully human anti-TNF antibody D2E7 slows radiographic disease progression in rheumatoid arthritis
35. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group
36. Succesful treatment of severe psoriatic arthritis with inflixmab
37. Enbrel® (Etanercept) in patients with psoriatic arthritis
38. Etanercept in Wegener's granulomatosis: Interim results of an open-label trial
39. Successful treatment of active ankylosing spondylitis with the anti-tumor cecrosis factor α (TNFα) monoclonal antibody infliximab
40. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure
41. Long-term follow-up of patients treated with inflixmab (anti-TNFα antibody) in clinical trials
42. Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis
43. The distribution of malignant neoplasms in rheumatoid arthritis (RA) is skewed compared to the general population
44. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxycholoroquine, or a combination of all three medications
45. Combination DMARD therapy with hydroxycholoroquine, sulfasalazine, and methotrexate
46. Methotrexate (M)-hydroxychloroquine (H)-Sulfasalazine (S) versus M-H or M-S for rheumatoid arthritis (RA): Results of a double-blind study